News You Can Use… Kristen Gray, PharmD Pete Koval, PharmD Cone Health Family Medicine April 4 th, 2016

New Drug Approval Odefsey ® (emtricitabine, rilpivirine tenofovir alafenamide) a new combination gained FDA approval for the treatment of HIV-1 infection Tenofovir “alafenamide” has improved renal and bone safety with high efficacy at lower total doses Similar to Genvoya ® replacing Stribild ® (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) 3/2/2016 FDA.gov

New Drug Approval Cinqair ® (reslizumab) is an IL-5 antagonist monoclonal antibody Indicated for add-on maintenance treatment of pts 18 and older with severe asthma and with an eosinophilic phenotype 3 mg/kg every 4 weeks in a healthcare setting (potential for anaphylaxis) 3/23/2016 FDA.gov

New Generic Approval Viagra ® (sildenafil) has been approved by the FDA in a generic formulation However, it will not be produced until December /9/2016 FDA.gov

New Generic Approval Nasonex ® (mometasone nasal spray) has been approved by the FDA in a generic formulation It is a once daily nasal steroid 3/22/2016 FDA.gov

New Generic Approval Voltaren Gel 1% ® (diclofenac) has been approved by the FDA in a generic formulation NSAID that is indicated for the relief of osteoarthritis of joints that is amenable to topical treatment 3/18/2016 FDA.gov

New Guidelines The CDC issued new guidelines on opioid prescriptions The guidelines recommend consider non-addictive pain relievers first Also recommends limiting opioid treatment to three days of treatment for acute pain 3/15/2016 CDC.gov

New Study Patients with Parkinson’s Disease (PD) receiving an antipsychotic had > 2x the risk of death than those not taking an antipsychotic Significantly higher risk of death with typical antipsychotics vs. atypical Must use antipsychotics with even more caution in elderly adults with PD 3/21/2016 JAMA Neurology

New Study PPIs shown to be gastroprotective in patients receiving dual antiplatelet therapy with clopidogrel and aspirin Fewer composite upper GI events in those receiving omeprazole than those receiving placebo (0.9% vs 2.6%, respectively, P=0.05) 3/21/2016 JAMA Neurology